the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R.sup.1 and R.sup.2 each independently represents hydrogen C.sub.1-4alkyl, NR.sup.9R.sup.10, C.sub.1-4alkyloxy; or R.sup.1 and R.sup.2 taken together with the carbon atom with which they are attached form a C.sub.3-6cycloalkyl; and where n is 2, either R.sup.1 or R.sup.2 may be absent to form an unsaturated bond; R.sup.3 represents a C.sub.6-12cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R.sup.3 represents a monovalent radical having one of the following formulae ##STR00001## ##STR00002## wherein said C.sub.6-12cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C.sub.1-4alkyl, C.sub.1-4alkyloxy, halo or hydroxy; Q represents Het.sup.1 or Ar.sup.2 wherein said C.sub.3-8cycloalkyl, Het.sup.1 or Ar.sup.2 are optionally substituted with one or where possible two or more substituents selected from halo, C.sub.1-4alkyl, C.sub.1-4alkyloxy, hydroxy, nitro, NR.sup.5R.sup.6, C.sub.1-4alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het.sup.2 and NR.sup.7R.sup.8, and C.sub.1-4alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl; R.sup.5 and R.sup.6 each independently represent hydrogen, C.sub.1-4alkyl, or C.sub.1-4alkyl substituted with phenyl; R.sup.7 and R.sup.8 each independently represent hydrogen or C.sub.1-4alkyl; R.sup.9 and R.sup.10 each independently represent hydrogen, C.sub.1-4alkyl or C.sub.1-4alkyloxycarbonyl; L represents C.sub.1-4alkyl; Het.sup.1 represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl; Het.sup.2 represents piperidinyl, pyrrolidinyl or morpholinyl; Ar.sup.2 represents phenyl, naphtyl or indenyl.